MGC DIAGNOSTICS CORP SAINT PAUL, MN (November10, 2015) ‐‐ MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, today announced it has signed a multi‐year partnership agreement with Pacific‐Medico CO., LTD., Tokyo, Japan, to exclusively market MGC Diagnostics' CCM Express indirect calorimeter system in Japan.
CCM Express is a proprietary advanced technology designed for use with patients in critical care environments requiring mechanical ventilation. The compact, portable, point‐of‐care design makes indirect calorimetry rapid and uncomplicated-while providing highly accurate measurements of resting energy expenditure (REE) and caloric utilization measurements.
Pacific Medico Co., Ltd President, Hidetoshi Tsubakiyama, commented, 'The partnership with MGC Diagnostics is the first step in bringing an effective patient management system into this demanding market. We are very excited about the future growth and opportunities of this partnership.'
Todd M. Austin, Chief Executive Officer of MGC Diagnostics, commented, 'The Japanese medical device market continues to experience positive growth. Entering this market is a significant step in expanding the global footprint of MGC Diagnostics. The CCM Express brings advanced technology to the physician, scientist and clinician challenged with providing care to critically ill patients where commonly used predictive equations often include errors in the prescription of nutritional therapies.'
Matthew S. Margolies, President of MGC Diagnostics, commented, 'The CCM Express is an important strategic addition to Pacific Medico's ventilation and respiratory care product offerings. Their strong reputation and history of superior customer support make Pacific Medico the right long‐term partner for MGC Diagnostics.'
Since 1998, Pacific Medico Co., Ltd has engaged in the development, production, distribution, and export of ventilators and respiratory products. Based in Tokyo, Japan, Pacific Medico's mission is in providing the speedy and timely delivery of respiratory care products in an effort to provide steady and reliable medical products. Pacific Medico Co., Ltd serves customers in Japan and Internationally. For more information about Pacific Medico Co., Ltd, visit http://www.pacific‐medico.com/.
MGC Diagnostics Corporation (NASDAQ: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and MediSoft SA subsidiaries, develops, manufactures and markets non‐invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward‐looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words 'believes,' 'expects,' 'anticipates,' 'intends' or similar expressions. For these forward‐looking statements, the Company claims the protection of the safe harbor for forward‐looking statements contained in federal securities laws. These forward‐looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward‐looking statements. For a list of these factors, see the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward Looking Statements', in the Company's Form 10‐K for the year ended October 31, 2014, and any updates in subsequent filings on Form 10‐Q or Form 8‐K under the Securities Exchange Act of 1934.
Contacts
Company Investors
Wesley W. Winnekins Joe Dorame, Robert Blum, Joe Diaz
MGC Diagnostics Corporation Lytham Partners, LLC
Chief Financial Officer (602) 889‐9700
(651) 484‐4874 mgcd@lythampartners.com
|
distributed by
|
